Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

The Medtronic Linq II implantable cardiac monitor.

The Medtronic Linq II implantable cardiac monitor.

News | Atrial Fibrillation | September 08, 2021
Continuous Heart Rhythm Monitoring and Anticoagulation Does Not Prevent Stroke
September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does...
read more
One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 
News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT)...
read more
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
Edoxaban May Be Effective Treatment for Atrial Fibrillation After TAVR 
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart...
read more
The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021.

News | Left Atrial Appendage (LAA) Occluders | August 16, 2021
FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation
August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage...
read more
Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

News | EP Lab | July 29, 2021
Oral Anticoagulants After Catheter Ablation Helps Reduce Stroke in High-Risk Patients
July 29, 2021 – Results of the STROKE-VT trial shows direct oral anticoagulants (DOACs) are more effective than aspirin...
read more
New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. How to anticoagulate COVID patients. How to prevent thrombus in COVID patients.

New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. Getty Images
 

Feature | Coronavirus (COVID-19) | July 15, 2021
Study Supports Early Anticoagulant Treatment to Reduce Death in Moderately Ill COVID-19 Patients
July 15, 2021 — COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly...
read more
Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.
 

News | Stents | June 30, 2021
FDA Clears Xience Stent for One Month DAPT in High Risk Bleeding Patients
June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug...
read more
Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future.

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future. Getty Images

News | Cardiovascular Clinical Studies | June 24, 2021
Study Shows ACC Registry Data Could Support Cardiac Clinical Trials
June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR)...
read more
FDA Clears Pradaxa as First Oral Anticoagulant for Children. Dabigatran, has been cleared by the FDA
News | Antiplatelet and Anticoagulation Therapies | June 21, 2021
FDA Clears Pradaxa as First Oral Anticoagulant for Children
June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate (...
read more
The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.
News | Peripheral Artery Disease (PAD) | May 17, 2021
Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease
May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the...
read more
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
Baby and Regular Strength Aspirin Equal in Cardiac Platelet Inhibition and Safety
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in...
read more
An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eloquis is not a good solution.

An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eliquis is not a good solution.

News | Structural Heart | May 15, 2021
TAVR Anticoagulation With Apixaban Not Superior to Standard Care
May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic...
read more
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
Long-term Dual Antiplatelet Therapy Benefits Reinforced in SCAI Late-breaking Study
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet...
read more
Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

News | Stents | April 06, 2021
Abbott’s Xience Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy for High Bleeding Risk Patients
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual...
read more
Videos | Coronavirus (COVID-19) | April 01, 2021
VIDEO: Antithrombotic Prophylaxis in COVID-19 Patients
Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an...
read more
© Copyright Wainscot Media. All Rights Reserved.